The table below shows Monte Rosa Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$123.67M
$75.62M
$0.00
-
-
-
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$141.50M
$121.56M
$111.27M
$85.06M
$57.16M
$24.00M
SG&A
$36.38M
GLUE annual revenue (10-K history)
Monte Rosa Therapeutics, Inc. reported annual revenue of $123.67M for fiscal year 2025. That is up 63.5% from $75.62M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
